Safety and toxicity profile of aztreonam

Abstract

Aztreonam is the first monocyclic beta-lactam antibiotic released for clinical use. Extensive toxicity and safety data for aztreonam in animals, healthy volunteers and adult patients have been accumulated previously; recently these studies have been extended to children. Overall the incidence of adverse clinical reactions caused by aztreonam is similar to or lower than that caused by comparison drugs. There is no evidence that aztreonam causes significant ototoxicity or nephrotoxicity; biochemical and hematologic abnormalities are rarely significant. Compared with the broad spectrum cephalosporins, aztreonam causes less disruption of normal gastrointestinal flora and consequently a lower incidence of diarrhea. Aztreonam does not displace bilirubin from albumin and penetrates readily into cerebrospinal fluid. Because of negligible immunologic cross-reactivity with other beta-lactams, aztreonam has been safely administered to patients with IgE-mediated penicillin hypersensitivity. These data suggest that aztreonam should be safe and well-tolerated in infants and children with infections caused by susceptible Gram-negative bacteria.